USA - engelsk - NLM (National Library of Medicine)

aspen global inc. - chlorambucil (unii: 18d0sl7309) (chlorambucil - unii:18d0sl7309) - chlorambucil 2 mg - leukeran (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and hodgkin’s disease. it is not curative in any of these disorders but may produce clinically useful palliation. chlorambucil should not be used in patients whose disease has demonstrated a prior resistance to the agent. patients who have demonstrated hypersensitivity to chlorambucil should not be given the drug. there may be cross-hypersensitivity (skin rash) between chlorambucil and other alkylating agents.

USA - engelsk - NLM (National Library of Medicine)

ax pharmaceutical corp - chlorambucil (unii: 18d0sl7309) (chlorambucil - unii:18d0sl7309) - chlorambucil 9.9 g in 10 g

USA - engelsk - NLM (National Library of Medicine)

ax pharmaceutical corp - chlorambucil (unii: 18d0sl7309) (chlorambucil - unii:18d0sl7309) - chlorambucil 99 g in 100 g

USA - engelsk - NLM (National Library of Medicine)

bluebay shandong co.,ltd - chlorambucil (unii: 18d0sl7309) (chlorambucil - unii:18d0sl7309) -

USA - engelsk - NLM (National Library of Medicine)

bluebay shandong co.,ltd - chlorambucil (unii: 18d0sl7309) (chlorambucil - unii:18d0sl7309) -

USA - engelsk - NLM (National Library of Medicine)

woodward pharma services llc - chlorambucil (unii: 18d0sl7309) (chlorambucil - unii:18d0sl7309) - leukeran (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and hodgkin’s disease. it is not curative in any of these disorders but may produce clinically useful palliation. chlorambucil should not be used in patients whose disease has demonstrated a prior resistance to the agent. patients who have demonstrated hypersensitivity to chlorambucil should not be given the drug. there may be cross-hypersensitivity (skin rash) between chlorambucil and other alkylating agents.

USA - engelsk - NLM (National Library of Medicine)

waylis therapeutics llc - chlorambucil (unii: 18d0sl7309) (chlorambucil - unii:18d0sl7309) - leukeran (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and hodgkin’s disease. it is not curative in any of these disorders but may produce clinically useful palliation. chlorambucil should not be used in patients whose disease has demonstrated a prior resistance to the agent. patients who have demonstrated hypersensitivity to chlorambucil should not be given the drug. there may be cross-hypersensitivity (skin rash) between chlorambucil and other alkylating agents.

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

aspen pharma trading limited, ireland 3016 lake drive, - dublin 24 +353 1 630 8400 - chlorambucil - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 2mg/tab - chlorambucil 2mg - chlorambucil

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspen pharma trading ltd - chlorambucil - oral tablet - 2mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - chlorambucil - oral tablet - 2mg